Dr Mira F Liebman received her medical degree from McGill University in 2005. She then completed pediatric residency training (2008) at McGill University. She trained at the Hospital for Sick Children (SickKids) in Pediatric Hematology-Oncology (2008-2011). She continued her training in Hematological Pathology at the University of Toronto (2011-2013). Dr Liebman is certified from the Royal College of Physicians and Surgeons of Canada in Pediatrics, Pediatric Hematology-Oncology and Hematological Pathology. Dr Liebman worked as a clinical assistant in hematology at the Hospital for Sick Children (2013-2016) before moving to Ottawa.
She practices as a pediatric hematologist and oncologist with interests in benign hematology and leukemia. Dr Liebman is cross-appointed to the department of Pathology and Laboratory Medicine, Division of Hematological Pathology. She is a practicing hematological pathologist at CHEO. Dr Liebman’s research interest is in blood conservation, iron deficiency anemia and leukemia.
Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation
We reviewed 22 pediatric patients with advanced myelodysplastic syndrome from a single center, diagnosed between January 2000 and December 2015. Of those, eight patients received off-label azacitidine before hematopoietic stem cell transplantation.
Immunohistochemistry (IHC) Predicts High Risk Cytogenetics in Acute Myeloid Leukemia (AML)
p53 Immunohistochemistry staining was performed on bone marrow clot and biopsy sections from AML patients diagnosed from January 2007-January 2009 and with successful cytogenetic analysis done by standard methods.